Fanciullacci M, Pietrini U, Nicolodi M, Sicuteri F
Funct Neurol. 1986 Oct-Dec;1(4):533-7.
A pupillopharmacological study has been carried out to evaluate the influence of two calcium blockers (CBs), flunarizine and nimodipine, on iris neurotransmission in migraine patients. Pretreatment with an oral dose of flunarizine or nimodipine markedly decreased the mydriasis induced by instillation of tyramine, a noradrenaline releaser. On the contrary, both drugs did not change the mydriasis by conjunctival phenylephrine, a postsynaptic adrenoceptor stimulant. In addition, nimodipine abolished the miosis caused by echothiophate iodide eye drops, a putative releaser of substance P from trigeminal sensory nerve endings. These findings suggest the idea that CBs treatment in migraine syndromes acts at presynaptic level by attenuating calcium-dependent release of monoaminergic and peptidergic neurotransmitters.
已开展一项瞳孔药理学研究，以评估两种钙通道阻滞剂（CBs）氟桂利嗪和尼莫地平对偏头痛患者虹膜神经传递的影响。口服氟桂利嗪或尼莫地平进行预处理，可显著降低由去甲肾上腺素释放剂酪胺滴眼引起的瞳孔散大。相反，这两种药物均未改变由突触后肾上腺素能受体兴奋剂苯肾上腺素结膜给药所致的瞳孔散大。此外，尼莫地平消除了由碘化依可碘酯滴眼液引起的瞳孔缩小，碘化依可碘酯被认为是三叉神经感觉神经末梢中P物质的释放剂。这些发现提示，偏头痛综合征的CBs治疗通过减弱单胺能和肽能神经递质的钙依赖性释放，作用于突触前水平。
